Vilanterol: Discovery, Development, Safety and Pharmacovigilance
Vilanterol is an inhaled long-acting beta2-adrenoceptor agonist (LABA) designed for bronchodilation over a once-daily dosing interval. It is encountered in marketed fixed-dose combinations rather than as a stand-alone rescue inhaler. This creates a central pharmacovigilance problem: a suspected reaction may arise from vilanterol's adrenergic activity, another active ingredient, the inhalation device, the underlying respiratory disease or their interaction. Naming the actual product and its constituents is essential before assessing causality or label listedness. [1â4]
- Vilanterol: Discovery, Development, Safety and Pharmacovigilance
- From beta-agonist pharmacology to GW642444
- The development strategy: an ingredient delivered through combinations
- Evidence that shaped authorisation and clinical use
- Safety: identifying the responsible exposure
- Translating the evidence into benefitârisk decisions
- Commercial lifecycle and regulatory boundaries
- From signal to defensible regulatory action
- Regional product-label listedness: USPI versus EU SmPC
- Practical pharmacovigilance workflow
- Key Takeaways
- References
- Regulatory Note
From beta-agonist pharmacology to GW642444
Short-acting beta2 agonists established that stimulation of airway smooth-muscle beta2 receptors could relieve bronchoconstriction. Their short duration left an unmet need for sustained bronchodilation in maintenance regimens. Earlier LABAs showed that prolonged activity was feasible, but a once-daily agent still required an appropriate balance of receptor pharmacology, duration, local exposure and systemic tolerability.
GSK's development candidate vilanterol, identified in early clinical publications as GW642444M, was evaluated for inherent 24-hour bronchodilator activity. The medicinal-chemistry goal was not merely greater potency: sustained airway effect needed to coexist with acceptable cardiovascular and metabolic effects at the proposed inhaled dose. A 602-participant randomised dose-ranging COPD trial compared 3, 6.25, 12.5, 25 and 50 micrograms once daily with placebo for 28 days. The study found dose-dependent trough FEV1 improvement; 25 and 50 micrograms produced clinically relevant improvements relative to placebo, without an apparent treatment-related signal in the measured short-term pulse, blood pressure, QTc, glucose or potassium outcomes. This does not establish absence of rare, delayed or susceptible-patient risks. [1]
Receptor mechanism and limits of selectivity
Beta2 receptor activation stimulates adenylyl cyclase and cyclic AMP signalling, promoting relaxation of airway smooth muscle. The inhaled route targets the bronchial tree but does not eliminate systemic absorption. Tachycardia, palpitations, tremor, hypokalaemia and hyperglycaemia remain pharmacologically plausible beta-agonist effects, particularly with excessive exposure or susceptible comorbidity. A selective beta2 agonist is not absolutely cardiac-neutral: receptor distribution, reflex effects, dose and interacting medicines matter. [2â4]
Vilanterol is metabolised primarily through CYP3A4 and is also a P-glycoprotein substrate. Strong CYP3A4 inhibitors may increase systemic exposure; this is relevant when an inhaler also contains fluticasone furoate, which has its own CYP3A4 interaction and systemic corticosteroid concerns. Mechanism-based plausibility must be separated from observed event frequency and established causal association. [2,3]
The development strategy: an ingredient delivered through combinations
Vilanterol's commercial history is tied to GSK's Ellipta platform and complementary molecules. Its fixed-dose combinations have distinct therapeutic rationales:
| Combination | Components | Clinical purpose | Attribution boundary |
|---|---|---|---|
| Relvar Ellipta (EU) / Breo Ellipta (US) | Fluticasone furoate + vilanterol | Inhaled anti-inflammatory treatment plus sustained bronchodilation | Candidiasis and steroid-related effects should not be attributed automatically to vilanterol |
| Anoro Ellipta | Umeclidinium + vilanterol | Two bronchodilator pathways for COPD maintenance | Antimuscarinic effects are not automatically beta-agonist effects |
| Trelegy Ellipta | Fluticasone furoate + umeclidinium + vilanterol | Triple maintenance treatment in selected obstructive airway disease | Trial effects belong to the tested triple regimen, not the LABA alone |
The two-partner and three-partner products are not interchangeable. Nor should their revenue be allocated wholesale to vilanterol when ranking the ingredient's commercial importance. The development programme combined a once-daily bronchodilator with existing inhaled corticosteroid and antimuscarinic strategies; the actual authorisation, indication, population and dose remain product- and jurisdiction-specific. [2â5]
Dose language and the device
The EU Relvar Ellipta SmPC describes 22 micrograms of delivered vilanterol corresponding to 25 micrograms pre-dispensed. US Breo Ellipta uses the pre-dispensed 25-microgram figure in its product-strength terminology. These are not two independently prescribed vilanterol doses. A pharmacovigilance narrative must record the label convention, device, strength and number of actuations before judging a suspected overdose or dispensing error. [2,3]
The Ellipta dry-powder inhaler requires the correct loading and inhalation sequence. Inadequate inspiratory technique, repeated opening and closing, dose-counter misunderstanding or use of multiple maintenance inhalers can lead to poor disease control or unintended duplicate LABA exposure. Such problems may masquerade as loss of efficacy or drug toxicity and require device-specific follow-up. [2â4]
Evidence that shaped authorisation and clinical use
Bronchodilation is not the same endpoint as exacerbation prevention
The initial vilanterol monotherapy dose-ranging trial assessed lung function over four weeks. Its FEV1 findings supported selection of a once-daily dose, but did not by themselves establish long-term prevention of severe exacerbations, mortality benefit or a rare-event safety profile. The later programme evaluated fixed combinations and longer clinical outcomes. [1]
The EMA's Relvar Ellipta assessment summarises asthma studies showing improvements in lung function compared with fluticasone furoate alone and placebo. One one-year asthma study reported at least one severe exacerbation in 13% of patients receiving fluticasone furoate/vilanterol 92/22 versus 16% receiving fluticasone furoate alone. This is evidence about the combined regimen in its trial population, not a stand-alone claim that vilanterol prevents exacerbations. [2]
For COPD, the EMA reports that two studies showed lower exacerbation rates with fluticasone furoate/vilanterol than vilanterol alone. That comparison helps distinguish the incremental effect of adding inhaled corticosteroid treatment to LABA maintenance. It also raises a separate benefitârisk question because inhaled corticosteroid-containing COPD regimens can increase pneumonia risk. A suspected pneumonia case requires evaluation of the steroid component, disease severity and concomitant factors rather than a simplistic LABA attribution. [2,3]
Dual bronchodilation: Anoro Ellipta
Umeclidinium blocks muscarinic-mediated bronchoconstriction, while vilanterol stimulates beta2-mediated relaxation. In the EMA's five pivotal Anoro studies, involving more than 5,600 patients, the authorised combination improved FEV1 compared with placebo and either individual component. The agency reports an average improvement of 167 mL over placebo after 24 weeks, and improvements of up to 95 mL over vilanterol alone and 52 mL over umeclidinium alone. These comparisons establish the rationale for complementary bronchodilation, but cannot be used to assign every combination adverse event to one ingredient. [4]
Anoro received EU marketing authorisation in May 2014. Relvar Ellipta received EU authorisation in November 2013; US Breo Ellipta's original approval was in 2013. The regional product names, age restrictions and indications differ. For example, the US Breo label used here includes paediatric asthma dosing, while the EU Relvar overview specifies asthma treatment from age 12; such differences must be checked against the precise current product label before discussing off-label exposure. [2â4]
Triple therapy and trial interpretation
Trelegy combines fluticasone furoate, umeclidinium and vilanterol. A comparison of triple therapy with dual therapy may demonstrate the incremental benefit and harm of adding a component in the studied population, but does not provide an independent randomised estimate of vilanterol's isolated contribution. IMPACT and other triple-therapy studies therefore belong in the lifecycle history as combination evidence, with careful attribution. Differences in baseline exacerbation risk, prior inhaled corticosteroid exposure, treatment discontinuation and outcome definitions complicate comparisons across trials.
Likewise, the SUMMIT programme investigated outcomes with fluticasone furoate/vilanterol in COPD patients with cardiovascular risk. Its primary mortality endpoint was not met. A non-significant mortality result must not be reframed as demonstrated survival benefit or as proof of no cardiovascular risk. The distinction between an endpoint not met, an observed numerical trend and a powered safety comparison is especially important in regulatory writing.
Safety: identifying the responsible exposure
Expected adrenergic effects
Excessive beta2 stimulation can cause tremor, headache, palpitations, tachycardia, altered blood potassium and glucose, and potentially arrhythmia in susceptible patients. A temporal relationship after a dose increase, duplicate LABA treatment, a strong CYP3A4 inhibitor or incorrect inhaler use can strengthen a mechanistic hypothesis; it does not by itself prove causality. Conversely, stable use without early symptoms does not exclude a later interaction or newly developed cardiac vulnerability. [2â4]
Serious asthma-related events and regimen context
LABA monotherapy in asthma has historically been associated with serious asthma-related events, prompting prominent class warnings. Vilanterol-containing asthma products are paired with an inhaled corticosteroid; the clinical safety question is about the approved combination regimen, not an imagined authorised vilanterol-only asthma product. The US Breo label addresses serious asthma-related events and explicitly states that the inhaler is not a rescue treatment for acute bronchospasm. An asthma deterioration report should capture reliever use, adherence to inhaled corticosteroid treatment, exacerbation severity and access to urgent care. [3]
Other components and competing explanations
Oral candidiasis, dysphonia, pneumonia in COPD and systemic corticosteroid effects may be related to fluticasone furoate exposure. Dry mouth and urinary retention may implicate umeclidinium's antimuscarinic activity. A combination-product report should preserve the suspect product as administered while documenting ingredient-level hypotheses; premature selection of vilanterol as the sole suspect may distort signal detection and listedness. [2â4]
Interactions and special populations
Strong CYP3A4 inhibition can raise vilanterol exposure. Beta-blockers can antagonise bronchodilation and, particularly when nonselective, may precipitate bronchospasm. Other sympathomimetics may increase adrenergic effects. The US Breo label also advises caution with monoamine oxidase inhibitors, tricyclic antidepressants and non-potassium-sparing diuretics in relevant contexts. Such cautions are not interchangeable with formal contraindications. [2,3]
When evaluating an event in an older COPD patient, consider arrhythmia history, hypoxaemia, diuretic use, renal and electrolyte disturbances, infection, inhaler duplication and baseline symptoms. These are competing or modifying factors, not automatic exclusions of a drug contribution.
Pregnancy, lactation and paediatric exposure
Product-specific regulatory scope matters particularly in populations where the balance between disease control and treatment risk differs. The November 2024 US Breo Ellipta label authorises asthma maintenance in patients aged 5 years and older, with an age-specific 50/25-microgram strength for ages 5â11 and 100/25 micrograms for ages 12â17. It is not an authorisation for vilanterol monotherapy or for the same paediatric dose in every country. The EU Relvar Ellipta label assessed here covers asthma from 12 years, not younger children. An unexpected paediatric exposure should therefore be assessed against the local authorised product, age, formulation and actual strength rather than by transferring the US indication to the EU. [2,3]
The US label reports insufficient human pregnancy data for a reliable drug-associated risk estimate and advises consideration of the maternal and fetal consequences of inadequately controlled asthma. The EU SmPC similarly notes limited pregnancy experience and advises a benefitârisk assessment. Animal exposure margins are not direct estimates of human fetal risk. For lactation, the absence of direct human-milk measurements for vilanterol is an evidence gap, not proof that the substance is absent from milk. These cases require documentation of maternal disease, timing, dose, co-exposures and infant outcome when known. [2,3]
Medication-error and overdose narratives
The US Breo label's overdose section describes potential effects of excessive beta-adrenergic stimulation, including tachycardia, arrhythmia, tremor, hypokalaemia and hyperglycaemia; it recommends cardiac monitoring in overdose. A case describing âfour puffsâ must clarify whether the patient inhaled four prepared doses, opened and closed the device repeatedly without inhaling, or confused a rescue inhaler with maintenance treatment. The pharmacological and device interpretations are very different. [3]
The combination's dry-powder presentation contains separate blister strips for the active ingredients. This does not mean that the patient can deliberately select one constituent or take only the LABA. Medication errors should be coded and narrated according to the event actually described, with product quality investigation where a device defect is plausible. A confirmed error without harm, a suspected adverse reaction after error and therapeutic failure from inadequate dose delivery are related but distinct safety records.
Translating the evidence into benefitârisk decisions
The evidence supporting vilanterol has several distinct layers. In-vitro receptor experiments establish a plausible pharmacological profile; short clinical dose-ranging studies establish bronchodilator activity; combination trials address clinically meaningful endpoints; and post-authorisation observation can detect patterns not apparent in registration studies. Each layer answers a different question, and a well-conducted pharmacovigilance review should not substitute one for another.
The chemistry behind once-daily activity
GSK medicinal chemists investigated saligenin beta2 agonists designed for prolonged airway action while incorporating features favouring systemic metabolic inactivation. Procopiou and colleagues described a series of compounds screened in receptor systems and isolated airway tissue; their compound 13f, later identified as vilanterol, combined high potency, receptor selectivity, rapid onset and sustained action in preclinical models. The paper also reports low oral bioavailability in rats and rapid metabolism. These findings explain the development rationale but cannot be read as a human guarantee of low systemic toxicity. The trifenatate salt supported an inhalable presentation; the active pharmacological entity is vilanterol. [6]
Subsequent pharmacology by Slack and colleagues used recombinant receptors, cAMP assays and human airway tissue. Vilanterol showed subnanomolar beta2-receptor affinity, beta2 selectivity comparable with salmeterol, and sustained bronchodilation in isolated human airways up to 22 hours after treatment. These experiments support the mechanistic rationale for a once-daily regimen. They do not prove that every patient will receive a full 24-hour clinical benefit or that receptor selectivity prevents tachyarrhythmia in high-risk patients. [7]
The negative asthma monotherapy experiment matters
A 12-week randomised asthma study by Lötvall and colleagues enrolled 347 patients whose asthma remained uncontrolled despite inhaled corticosteroid treatment. Participants received vilanterol, salmeterol or placebo while continuing background inhaled corticosteroids. Although lung function improved numerically from baseline in all groups, the adjusted primary comparison of vilanterol with placebo was 70 mL and not statistically significant (P = 0.244). The investigators noted an unexpectedly large placebo response and could not draw a meaningful treatment-difference conclusion. [8]
This result should not be concealed in an ingredient history merely because later combination products obtained approval. It shows why a numerical change within an active arm is not the same as a treatment effect relative to control. It also illustrates the effect that adherence to background treatment, trial participation and endpoint choice may have on interpretation. The study did not establish a negative long-term safety finding, nor did it test an approved vilanterol-only asthma regimen. It is a trial with an inconclusive primary efficacy comparison in a specific design.
SUMMIT: a large study with a negative primary endpoint
SUMMIT enrolled patients with moderate COPD and established or heightened cardiovascular risk. In the intention-to-treat population of 16,485, the fluticasone furoate/vilanterol combination did not significantly reduce all-cause mortality relative to placebo: hazard ratio 0.88, 95% CI 0.74â1.04, P = 0.137. Vilanterol alone also did not significantly reduce mortality: hazard ratio 0.96, 95% CI 0.81â1.14, P = 0.655. The composite cardiovascular endpoint for vilanterol versus placebo had hazard ratio 0.99, 95% CI 0.80â1.22. [9]
These estimates are valuable but bounded. A confidence interval crossing unity does not demonstrate equivalence or absence of risk. The population was enriched for cardiovascular risk but excluded some very severe disease; event ascertainment and treatment exposure differed from ordinary clinical practice. The trial found secondary evidence on exacerbations and FEV1 decline, but the failed primary mortality endpoint means secondary findings should be interpreted with appropriate statistical restraint. A safety narrative that says âSUMMIT proved cardiovascular safetyâ would overstate the study.
IMPACT: the combination comparison and its trade-off
IMPACT randomised 10,355 symptomatic COPD patients with an exacerbation history to once-daily fluticasone furoate/umeclidinium/vilanterol triple therapy, fluticasone furoate/vilanterol, or umeclidinium/vilanterol. The annual rate of moderate or severe exacerbations was 0.91, 1.07, and 1.21, respectively. The triple-versus-FF/VI rate ratio was 0.85 (95% CI 0.80â0.90), while the triple-versus-UMEC/VI rate ratio was 0.75 (95% CI 0.70â0.81). The triple regimen was also associated with more clinician-diagnosed pneumonia than UMEC/VI (hazard ratio 1.53, 95% CI 1.22â1.92). [10]
The comparison with FF/VI estimates the clinical effect of adding umeclidinium to a background containing vilanterol and fluticasone furoate; the comparison with UMEC/VI estimates the effect of adding fluticasone furoate to a background containing vilanterol and umeclidinium. Neither contrast estimates vilanterol's isolated effect, because vilanterol was present in every arm. Prior inhaled corticosteroid exposure and withdrawal at randomisation are relevant when interpreting exacerbation differences. The pneumonia trade-off is principally an inhaled corticosteroid benefitârisk consideration, not proof of a vilanterol-specific pneumonia mechanism.
Asthma comparison with a twice-daily reference regimen
An asthma trial comparing once-daily fluticasone furoate/vilanterol 100/25 with twice-daily fluticasone propionate/salmeterol 250/50 enrolled 806 patients. After 24 weeks, adjusted differences in 24-hour weighted mean FEV1 were not statistically significant: â37 mL, 95% CI â88 to 15, P = 0.162. The result supports a measured comparison in that trial, but absence of a statistically significant difference is not, without a prespecified noninferiority design and margin, proof of therapeutic equivalence. [11]
Commercial lifecycle and regulatory boundaries
A platform ingredient rather than a stand-alone marketed product
Vilanterol's history is inseparable from the Ellipta platform and a family of fixed-dose combinations. The EU authorised Relvar Ellipta in November 2013 and Anoro Ellipta in May 2014; the United States initially approved Breo Ellipta in 2013. The fixed combinations allow the same LABA to appear in products with different therapeutic purposes, safety issues, indication restrictions and co-ingredient risks. [2â4]
A financial analysis should therefore start from the specific marketed products and the reporting entity. Manufacturer-reported sales for a dual or triple inhaler cannot be assigned wholly to vilanterol, and sales of multiple brands or regions may overlap. A legitimate ingredient lifecycle story can explain the value of the shared LABA platform without inventing an ingredient-specific global revenue figure. Changes in brand availability, market authorisation, intellectual-property protection and generic competition must be verified separately by jurisdiction and year; this article makes no unverified claim of a worldwide patent expiry or generic market share.
The Ellipta device is also a lifecycle asset, but device familiarity can create a misleading assumption that strengths and ingredients are interchangeable. A patient changing from Relvar to Trelegy retains vilanterol but gains umeclidinium; changing from Anoro to Trelegy retains umeclidinium and vilanterol but gains fluticasone furoate. This can be clinically appropriate when prescribed, but simultaneous use of old and new devices can duplicate maintenance drugs. Accurate medication reconciliation is therefore both a clinical and a PV control.
Why the safety evidence must be stratified
For a signal concerning palpitations, compare exposure patterns across products, but recognise that the patients receiving different inhalers may differ systematically in COPD severity, exacerbation history and comorbidities. Apparent product-level differences can arise from channeling, prescribing selection, device training or concomitant medications. When observational comparisons are made, record confounding control, exposure definitions, follow-up windows, outcomes and uncertainty. No spontaneous-report disproportionality measure by itself estimates incidence or proves an ingredient-specific causal mechanism.
For a suspected asthma-related death or hospitalisation, distinguish historical LABA monotherapy class evidence from the observed combination exposure. A report involving Breo Ellipta should capture adherence to the inhaled corticosteroid component and whether the patient had additional LABA exposure, without suggesting that a patient can selectively omit the steroid from a correctly used fixed-dose inhaler. For a suspected pneumonia signal, stratify by COPD and asthma indication and corticosteroid dose. For urinary retention, confirm whether the actual product contains umeclidinium; vilanterol alone is not a muscarinic antagonist.
From signal to defensible regulatory action
A practical safety review begins with a case definition and an exposure definition. A broad code such as âheart rate increasedâ may combine transient sinus tachycardia, atrial fibrillation, palpitations and measurement artefact. Clinically meaningful subgroups require medical review of the original narratives, seriousness criteria, ECG information, alternative explanations and time course. The same care is needed for a signal of âlack of efficacy,â which may include device misuse, severe disease progression, nonadherence, supply interruption and true pharmacodynamic nonresponse.
An emerging issue should be evaluated against clinical trial exposure, label history, known pharmacology, spontaneous reports, published literature and, where feasible, appropriately designed observational studies. The decision trail should show what evidence was available, what was missing, why the issue was escalated or closed, and when it will be revisited. Regulatory obligations depend on jurisdiction and product; this describes good PV practice rather than inventing a universal legal deadline.
When preparing a periodic benefitârisk assessment, the central question is whether the observed risks remain acceptable in the context of demonstrated benefits for the authorised regimen. For vilanterol, a meaningful assessment might contrast maintained bronchodilation and exacerbation outcomes with cardiovascular, metabolic, hypersensitivity and device-related concerns, while explicitly assigning the pneumonia contribution to the steroid-containing regimen rather than the LABA by assumption. Such disciplined attribution is more useful than simply collecting all adverse events ever reported with an Ellipta product.
Regional product-label listedness: USPI versus EU SmPC
Documents assessed on 27 October 2026. The US comparator is Breo Ellipta, fluticasone furoate/vilanterol inhalation powder, DailyMed SPL version 29 with effective date 7 November 2024 (sections 4â7, 12 and 17). The EU comparator is Relvar Ellipta, fluticasone furoate/vilanterol, EMA centrally authorised product information last updated 10 April 2025 (SmPC sections 4.3â4.8 and 5.2). These are combination-product labels; there is no vilanterol-only public label in this comparison. [2,3]
| Assessment dimension | US Breo Ellipta USPI | EU Relvar Ellipta SmPC | Interpretation |
|---|---|---|---|
| Product and dose convention | Vilanterol 25 micrograms per actuation in US strength designation | 22 micrograms delivered corresponds to 25 micrograms pre-dispensed | Different presentation conventions, not evidence of different administered regimens |
| Indication/population | COPD maintenance and asthma maintenance, including labelled paediatric strengths | COPD and asthma with EU-specific population and strength restrictions | Do not extrapolate paediatric US authorisation to the EU |
| Acute symptoms | Not indicated for relief of acute bronchospasm | Maintenance therapy, not an acute reliever | A deterioration case needs rescue-treatment and adherence history |
| Adrenergic effects | Warnings and adverse-reaction sections discuss beta-agonist cardiovascular/metabolic risks | SmPC warnings and section 4.8 provide product-specific reactions and frequency categories | A warning mention is not necessarily a section-4.8 adverse-reaction entry |
| Inhaled corticosteroid effects | Candidiasis, pneumonia and systemic steroid precautions | Corresponding corticosteroid and COPD pneumonia information | Do not attribute these automatically to vilanterol |
| Drug interactions | CYP3A4 inhibitors, beta-blockers, MAOIs/TCAs, diuretics | CYP3A4 inhibitors, beta-blockers and sympathomimetic combinations | Interaction text is not itself proof of an observed adverse reaction |
Reaction-by-reaction comparison of the assessed combination labels
This comparison deliberately separates the US section 6 clinical-trial/postmarketing reaction material, US section 5 warnings, and EU section 4.8 tabulated adverse reactions. The reaction is listed for the combination product; the table cannot establish attribution to vilanterol alone. US incidence thresholds and EU frequency bands are not directly interchangeable. [2,3]
| Reaction or concern | US Breo Ellipta, revised November 2024 | EU Relvar Ellipta, SmPC 4.8 updated April 2025 | Assessment |
|---|---|---|---|
| Headache | Listed in COPD and asthma section 6 trial reactions | Very common in 4.8 | Listed in both products |
| Nasopharyngitis | Listed in section 6 trial reactions | Very common in 4.8 | Listed in both products |
| Oropharyngeal candidiasis | Listed in section 6 and discussed in warning 5.4 | Common candidiasis of mouth and throat in 4.8 | Listed in both; mechanistically linked principally to inhaled steroid exposure |
| Pneumonia | Listed in COPD trial data and warning 5.5 | Common in 4.8, with COPD-specific discussion | Listed in both; interpretation requires indication and inhaled corticosteroid context |
| Palpitations and tachycardia | Listed in postmarketing section 6.3; also addressed in warning 5.12 | Rare palpitations and rare tachycardia in 4.8 | Listed in both; US voluntary postmarketing reports do not establish a frequency |
| Extrasystoles | Included among reactions occurring in at least 2% in the US 12-month asthma trial (section 6.2); warning 5.12 also mentions extrasystoles | Uncommon in 4.8 | Listed in both, with different study and frequency frameworks |
| Tremor | Listed in postmarketing section 6.3 | Rare in 4.8 | Listed in both; US frequency cannot be estimated from voluntary reports |
| Hyperglycaemia | Listed as hyperglycemia in postmarketing section 6.3 and addressed in warning 5.17 | Uncommon in 4.8 | Listed in both; US frequency is not established |
| Paradoxical bronchospasm | Listed in postmarketing section 6.3 and addressed in warning 5.10 | Rare in 4.8 | Listed in both; potentially serious and requires prompt clinical attention |
| Hypersensitivity, including anaphylaxis | Listed in postmarketing section 6.3 (anaphylaxis, angioedema, rash, urticaria); warning 5.11 | Rare hypersensitivity including these manifestations in 4.8 | Listed in both; EU supplies a frequency band, US postmarketing section does not |
The labels' presentation differs materially: the US section 6.3 lists voluntary postmarketing reports without estimable frequency, whereas the EU section 4.8 assigns frequency bands. An event described only in a warning can also be clinically important. The term ânot verifiedâ must never be treated as âunlisted.â A sponsor's applicable reference safety information and local assessment conventions determine trial expectedness and reporting, not this public-label comparison. [2,3]
Why a combination label cannot be treated as an ingredient monograph
Both labels combine an inhaled corticosteroid and a LABA. The regulatory adverse-reaction table is therefore the product's safety description, not an experiment in ingredient attribution. In a case of palpitations after Breo, vilanterol is pharmacologically plausible, but underlying hypoxaemia, rescue salbutamol and other causes must still be assessed. In a case of pneumonia after the same inhaler, the inhaled corticosteroid is particularly relevant, while baseline COPD severity and infection exposure are major competing factors. For Trelegy, an additional antimuscarinic component complicates attribution further.
A different product such as Anoro Ellipta may have its own reaction frequencies, contraindications and warning text. Even when it contains the same 22-microgram delivered vilanterol dose, its label is not interchangeable with Relvar's. The correct comparison is product to product, at the relevant dates, rather than ingredient to ingredient without a stand-alone label. [2â4]
Listedness rule. For a named case reaction, determine whether the exact event term or medically justified equivalent is listed in the relevant dated product's adverse-reaction section, or appears only in a warning, interaction or precaution. Record which section was used. This table identifies principal differences and does not purport to reproduce every adverse reaction or frequency in the labels. The label must be rechecked at the case assessment date, particularly when the formulation, strength or jurisdiction differs.
Public USPI and SmPC listedness is not interchangeable with company core safety information, reference safety information used for clinical-trial expectedness, individual case causality or expedited-reporting obligations. A reaction unlisted in one document may be listed in another. The absence of an accessible label for a hypothetical vilanterol-only product is not evidence that a reaction is unlisted. [2,3]
Practical pharmacovigilance workflow
Case intake and follow-up
First record the exact brand, active substances, strength, device, country, lot where available, dates, number of inhalations and the patient's technique. Confirm whether the patient also used another LABA, LAMA or inhaled corticosteroid product. Record the event's onset, seriousness, treatment, outcome, dechallenge/rechallenge if known, and whether an acute exacerbation preceded or followed the event.
Next identify competing causes and modifiers: respiratory infection, COPD/asthma severity, cardiac disease, oxygenation, electrolyte values, rescue bronchodilator frequency and interacting medicines. For an apparent lack-of-effect report, ask whether the inhaler was primed or operated correctly and whether the patient inhaled the dose. For palpitations, ask about timing after inhalation, excess doses and concomitant sympathomimetics. These are suggested follow-up practices, not a substitute for applicable reporting rules.
Signal review and governance
Aggregate case series should be stratified by actual combination product, indication, age, device and suspected co-ingredients before drawing conclusions. Assess background incidence and exposure where suitable denominators exist. Spontaneous-report counts cannot establish incidence or causal effect on their own. Evaluate label history and regulatory actions alongside clinical-trial and pharmacoepidemiological evidence.
A useful regulatory precedent is the EMA PRAC review of a post-authorisation observational cardiovascular/cerebrovascular safety study of umeclidinium/vilanterol and umeclidinium compared with tiotropium. The September 2024 CHMP scientific conclusion supported removing the relevant umeclidinium and umeclidinium/vilanterol products from additional monitoring after fulfilment of the imposed study obligation; this is a regulatory administrative conclusion with a defined evidence scope, not a general absence-of-risk finding. This is not proof that every cardiovascular event is unrelated to vilanterol, nor a replacement for case-level evaluation. [5]
Illustrative inspection question
Hypothetical scenario: a report describes tachycardia after a switch from one COPD inhaler to a triple Ellipta product. The original record says only âvilanterol overdose.â An inspection-ready assessment should show the source documentation for both inhalers, the number of actuations, whether another LABA remained active, device counselling, co-medications, seriousness assessment, coding rationale, applicable label version and the reason for assigning or not assigning individual ingredients as suspects. A documented uncertainty is preferable to a confident but unsupported ingredient attribution.
Key Takeaways
Vilanterol is a once-daily LABA developed as GW642444 and commercialised within dual and triple inhaled maintenance combinations. Its pharmacological risks are those of beta2 stimulation, modified by dose, co-medication and patient susceptibility. Efficacy and adverse-event findings from a fixed combination must be interpreted in the context of that combination. US 25-microgram pre-dispensed and EU 22-microgram delivered designations require careful reconciliation. Regulatory listedness is product-, version- and jurisdiction-specific; it is not synonymous with causality or clinical-trial expectedness.
References
- Hanania NA et al. The efficacy and safety of the novel long-acting beta2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial. Chest. 2012. PMID 22241764. https://pubmed.ncbi.nlm.nih.gov/22241764/
- European Medicines Agency. Relvar Ellipta: EPAR and EU product information, last updated 10 April 2025. https://www.ema.europa.eu/en/medicines/human/EPAR/relvar-ellipta
- DailyMed. Breo Ellipta (fluticasone furoate/vilanterol trifenatate) US prescribing information, SPL version 29, effective 7 November 2024. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=96428df1-ea05-431a-98d3-1ec2c4b63878
- European Medicines Agency. Anoro Ellipta: EPAR and EU product information, updated 31 July 2025. https://www.ema.europa.eu/en/medicines/human/EPAR/anoro-ellipta
- European Medicines Agency. Scientific conclusions, 19 September 2024, final imposed PASS Study 201038 for umeclidinium and umeclidinium/vilanterol products. https://www.ema.europa.eu/en/documents/scientific-conclusion/laventair-ellipta-h-c-psr-s-0048-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf
- Procopiou PA et al. Synthesis and structureâactivity relationships of long-acting beta2 adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approach. J Med Chem. 2010;53:4522â4530. PMID 20462258. https://pubmed.ncbi.nlm.nih.gov/20462258/
- Slack RJ et al. In vitro pharmacological characterization of vilanterol. J Pharmacol Exp Ther. 2013;344:218â230. PMID 23131596. https://pubmed.ncbi.nlm.nih.gov/23131596/
- Lötvall J et al. Comparison of vilanterol with placebo and salmeterol in asthma uncontrolled by inhaled corticosteroids. J Negat Results Biomed. 2014;13:9. PMID 24928338. https://pubmed.ncbi.nlm.nih.gov/24928338/
- Vestbo J et al. Fluticasone furoate and vilanterol and survival in COPD with heightened cardiovascular risk (SUMMIT). Lancet. 2016;387:1817â1826. PMID 27203508. https://pubmed.ncbi.nlm.nih.gov/27203508/
- Lipson DA et al. Once-daily single-inhaler triple versus dual therapy in COPD (IMPACT). N Engl J Med. 2018;378:1671â1680. DOI 10.1056/NEJMoa1713901. https://www.nejm.org/doi/full/10.1056/NEJMoa1713901
- Woodcock A et al. Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol in persistent asthma. PMID 23846316. https://pubmed.ncbi.nlm.nih.gov/23846316/
Regulatory Note
This educational review distinguishes verified public-label statements, clinical evidence and recommended pharmacovigilance practice. Regulatory status, SmPCs and USPI can change. Consult the current authorised product information and applicable local rules for individual decisions. Neither a suspected reaction nor its presence in a label establishes individual causality.